Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT05993234
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
257 Enrollment(s)
76 Study location(s)
OBSERVATIONAL (None)
HER2-positive Advanced Gastric Cancer


HER2-positive Gastroesophageal Junction Adenocarcinoma
RECRUITING
NCT05945732
DESTINY Breast Respond HER2-low Europe
1,155 Enrollment(s)
210 Study location(s)
OBSERVATIONAL (None)
Unresectable Breast Cancer


Metastatic Breast Cancer


HER2-low Expressing Breast Cancer
RECRUITING
NCT05372614
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
30 Enrollment(s)
18 Study location(s)
INTERVENTIONAL (PHASE1)
Metastatic Malignant Solid Neoplasm


Unresectable Malignant Solid Neoplasm
ACTIVE_NOT_RECRUITING
NCT04538742
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
245 Enrollment(s)
72 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Metastatic Breast Cancer
WITHDRAWN
NCT02493322
Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
0 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE3)
Essential Arterial Hypertension
WITHDRAWN
NCT02483936
Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control
0 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE3)
Arterial Hypertension
RECRUITING
NCT07195149
Optimal Antiplatelet Therapy in Patients After Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)
1,703 Enrollment(s)
18 Study location(s)
INTERVENTIONAL (PHASE3)
Chronic Coronary Syndrome


Stable Coronary Artery Disease CAD
RECRUITING
NCT06819007
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
582 Enrollment(s)
110 Study location(s)
INTERVENTIONAL (PHASE3)
Ovarian Cancer